Global Acute Myeloid Leukemia Treatment Market Report and Forecast 2023-2031

Global Acute Myeloid Leukemia Treatment Market Report and Forecast 2023-2031

Global Acute Myeloid Leukemia Treatment Market Outlook

The global acute myeloid Leukemia treatment market is expected to grow at a compound annual growth rate (CAGR) of 11.4% during the forecast period of 2023-2031. The increasing prevalence of AML and the development of new therapies are the primary drivers of market growth.

Acute Myeloid Leukemia Treatment Market: Introduction

Acute myeloid Leukemia (AML) is a type of cancer that affects the blood and bone marrow. It is characterized by the rapid growth of abnormal white blood cells, which can interfere with the production of normal blood cells in the bone marrow. AML is a serious and life-threatening disease that can spread quickly to other parts of the body if not treated promptly.

The exact cause of AML is unknown, but risk factors include exposure to certain chemicals, radiation, and genetic disorders. Symptoms of AML include fatigue, weakness, shortness of breath, easy bruising or bleeding, fever, and infections. Treatment options for AML include chemotherapy, targeted therapy, and stem cell transplantation. The choice of treatment depends on factors such as the patient's age, overall health, and the type and stage of AML. Early diagnosis and treatment are essential for a better prognosis in patients with AML.

Acute Myeloid Leukemia Epidemiology

Acute Myeloid Leukemia (AML) is a relatively rare disease, but it is the most common type of acute Leukemia in adults. The incidence of AML increases with age, and the disease is more commonly diagnosed in people over the age of 60. AML affects men and women equally, and there is no significant difference in the incidence of AML between different racial or ethnic groups.

The exact prevalence of AML is difficult to determine, as the disease is often misdiagnosed or underdiagnosed. However, it is estimated that there are approximately 20,000 new cases of AML diagnosed each year in the United States, with a slightly higher incidence in men than in women. Certain genetic disorders, such as Down syndrome, are associated with an increased risk of developing AML. Exposure to certain chemicals, such as benzene, and radiation are also known risk factors for the development of AML.

Acute Myeloid Leukemia Treatment Market Segmentations

The market can be categorised into diagnosis method, therapy type, and treatment channel.

Market Breakup by Diagnosis Methods

  • Biopsy and Bone Marrow Aspiration
  • Complete Blood Count and Differential
  • Philadelphia Chromosome Presence
  • Spinal Tap (Lumbar Puncture) and Cerebrospinal Fluid (CSF) Analysis
  • Immunophenotyping or Phenotyping by Flow Cytometry
  • Polymerase Chain Reaction (PCR)
  • Others
Market Breakup by Therapy Type
  • Targeted Drugs
  • Chemotherapy
  • Stem/Bone Marrow Treatment
  • Radiation Therapy
  • Others
Market Breakup by Treatment Channel
  • Public
  • Private
Acute Myeloid Leukemia Treatment Market Breakup by Region
  • North America
  • United States of America
  • Canada
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others
Acute Myeloid Leukemia Treatment Market Scenario

The global acute myeloid Leukemia (AML) treatment market is expected to witness significant growth in the coming years. The market is driven by the increasing prevalence of AML and the development of new therapies.

Chemotherapy is currently the most common form of treatment for AML, accounting for over 50% of the market share in 2021. However, targeted therapy, which includes drugs such as venetoclax and midostaurin, is expected to grow at a faster rate during the forecast period. Targeted therapy is more specific and less toxic than chemotherapy, making it an attractive option for patients with AML.

North America dominates the AML treatment market, accounting for over 40% of the global market share. The presence of a well-established healthcare infrastructure and a high prevalence of AML in the region is driving market growth. Europe is the second-largest market for AML treatment, with the growing adoption of novel therapies and the increasing focus on precision medicine driving market growth.

The Asia Pacific region is expected to witness the highest growth rate during the forecast period, owing to the increasing prevalence of AML in the region and the rising healthcare expenditure. The growing awareness about AML and the availability of new treatment options are also expected to contribute to market growth.

Key Players in the Global Acute Myeloid Leukemia Treatment Market

The report gives an in-depth analysis of the key players involved in the acute myeloid Leukemia treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
  • Daiichi Sankyo Company, Limited
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi S.A.
  • Pfizer Inc.
  • Oncolyze Inc.
  • Syndax Pharmaceuticals Inc.
  • AbbVie Inc.
  • Amgen Inc.
  • Servier Pharmaceutical LLC
  • F. Hoffmann-La Roche Ltd
  • Viracta Therapeutics, Inc.
  • Novartis AG
  • Otsuka Holdings Co. Ltd


1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Acute Myeloid Leukemia Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation and Regulatory Framework
6.1 Emerging Therapies and Clinical Trials
6.2 Patent Landscape
6.2.1 Patent Overview
6.2.1.1 Patent Status and Expiry
6.2.1.2 Timelines from Drug Development to Commercial Launch
6.2.1.3 New Drug Application
6.2.1.3.1 Documentation and Approval Process
6.3 Cost of Treatment
6.4 Regulatory Framework
6.4.1 Regulatory Overview
6.4.1.1 US FDA
6.4.1.2 EU EMA
6.4.1.3 INDIA CDSCO
6.4.1.4 JAPAN PMDA
6.4.1.5 Others
7 Challenges and Unmet Needs
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop-out Analysis
7.3 Awareness and Prevention Gaps
8 Global Acute Myeloid Leukemia Treatment Market
8.1 Global Acute Myeloid Leukemia Treatment Market Overview
8.2 Global Acute Myeloid Leukemia Treatment Market Analysis
8.2.1 Market Overview
8.2.1.1 Global Acute Myeloid Leukemia Treatment Market Historical Value (2016-2022)
8.2.1.2 Global Acute Myeloid Leukemia Treatment Market Forecast Value (2023-2031)
8.3 Global Acute Myeloid Leukemia Treatment Market by Diagnosis Method
8.3.1 Market Overview
8.3.1.1 Biopsy and Bone Marrow Aspiration
8.3.1.2 Complete Blood Count (CBC) and Differential
8.3.1.3 Philadelphia Chromosome’s Presence
8.3.1.4 Spinal Tap (lumbar puncture) and Cerebrospinal Fluid (CSF) Analysis
8.3.1.5 Immunophenotyping or Phenotyping by Flow Cytometry
8.3.1.6 Polymerase Chain Reaction (PCR)
8.3.1.7 Others
8.4 Global Acute Myeloid Leukemia Treatment Market by Therapy Type
8.4.1 Market Overview
8.4.1.1 Targeted Drugs
8.4.1.2 Chemotherapy
8.4.1.3 Stem/Bone Marrow Transplant
8.4.1.4 Radiation Therapy
8.4.1.5 Others
8.5 Global Acute Myeloid Leukemia Treatment Market by Treatment Channel
8.5.1 Market Overview
8.5.1.1 Public
8.5.1.2 Private
8.6 Global Acute Myeloid Leukemia Treatment Market by Region
8.6.1 Market Overview
8.6.1.1 North America
8.6.1.2 Europe
8.6.1.3 Asia Pacific
8.6.1.4 Latin America
8.6.1.5 Middle East and Africa
9 North America Acute Myeloid Leukemia Treatment Market
9.1 Market Share by Country
9.2 United States of America
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3 Canada
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
10 Europe Acute Myeloid Leukemia Treatment Market
10.1 Market Share by Country
10.2 United Kingdom
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3 Germany
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
10.4 France
10.4.1 Historical Trend (2016-2022)
10.4.2 Forecast Trend (2023-2031)
10.5 Italy
10.5.1 Historical Trend (2016-2022)
10.5.2 Forecast Trend (2023-2031)
10.6 Others
11 Asia Pacific Acute Myeloid Leukemia Treatment Market
11.1 Market Share by Country
11.2 China
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3 Japan
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4 India
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
11.5 ASEAN
11.5.1 Historical Trend (2016-2022)
11.5.2 Forecast Trend (2023-2031)
11.6 Australia
11.6.1 Historical Trend (2016-2022)
11.6.2 Forecast Trend (2023-2031)
11.7 Others
12 Latin America Acute Myeloid Leukemia Treatment Market
12.1 Market Share by Country
12.2 Brazil
12.2.1 Historical Trend (2016-2022)
12.2.2 Forecast Trend (2023-2031)
12.3 Argentina
12.3.1 Historical Trend (2016-2022)
12.3.2 Forecast Trend (2023-2031)
12.4 Mexico
12.4.1 Historical Trend (2016-2022)
12.4.2 Forecast Trend (2023-2031)
12.5 Others
13 Middle East and Africa Acute Myeloid Leukemia Treatment Market
13.1 Market Share by Country
13.2 Saudi Arabia
13.2.1 Historical Trend (2016-2022)
13.2.2 Forecast Trend (2023-2031)
13.3 United Arab Emirates
13.3.1 Historical Trend (2016-2022)
13.3.2 Forecast Trend (2023-2031)
13.4 Nigeria
13.4.1 Historical Trend (2016-2022)
13.4.2 Forecast Trend (2023-2031)
13.5 South Africa
13.5.1 Historical Trend (2016-2022)
13.5.2 Forecast Trend (2023-2031)
13.6 Others
14 Acute Myeloid Leukemia Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter’s Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Industry Events, Initiatives, and Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 Daiichi Sankyo Company, Limited
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.1.5 Certifications
15.2 Teva Pharmaceutical Industries Ltd.
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 Sanofi S.A.
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 Pfizer Inc.
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 Oncolyze Inc.
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 Syndax Pharmaceuticals Inc.
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 AbbVie Inc.
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
15.8 Amgen Inc.
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.8.5 Certifications
15.9 Servier Pharmaceutical LLC
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.9.5 Certifications
15.10 F. Hoffmann-La Roche Ltd
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
15.10.5 Certifications
15.11 Viracta Therapeutics, Inc.
15.11.1 Company Overview
15.11.2 Product Portfolio
15.11.3 Demographic Reach and Achievements
15.11.4 Mergers and Acquisitions
15.11.5 Certifications
15.12 Novartis AG
15.12.1 Company Overview
15.12.2 Product Portfolio
15.12.3 Demographic Reach and Achievements
15.12.4 Mergers and Acquisitions
15.12.5 Certifications
15.13 Otsuka Holdings Co. Ltd
15.13.1 Company Overview
15.13.2 Product Portfolio
15.13.3 Demographic Reach and Achievements
15.13.4 Mergers and Acquisitions
15.13.5 Certifications
16 Global Acute Myeloid Leukemia Treatment Market- Drug Distribution Model (Additional Insight)
16.1 Overview
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
17.3 Out-of-Pocket

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings